TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07282249: A Multicenter, Randomized, Placebo-Controlled and Positive-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B

Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 630 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07282249 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07282249 Rescue Dossier →